4.4 Article

LDL cholesterol in early pregnancy and offspring cardiovascular disease risk factors

Journal

JOURNAL OF CLINICAL LIPIDOLOGY
Volume 10, Issue 6, Pages 1369-1378

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2016.08.016

Keywords

Hypercholesterolemia; Pregnancy; Risk factors; Children; LDL

Funding

  1. Abbot
  2. Apotek 1
  3. Amgen
  4. Genzyme
  5. Melk.no
  6. Mills DA
  7. MSD
  8. Norwegian Medical Association
  9. Norwegian Directorate for Health
  10. Oslo Economics
  11. Pfizer
  12. Sanofi
  13. Norwegian Medicines Agency
  14. Lilly
  15. Tine DA
  16. Olympic Seafood
  17. Pronova

Ask authors/readers for more resources

BACKGROUND: Vast amounts of data show associations between maternal obesity, dysglycemia, diabetes, and undernutrition during pregnancy and increased cardiovascular disease risk in offspring. However, elevated maternal LDL cholesterol (LDL-C) in pregnancy and offspring cardiovascular disease (CVD) risk has scarcely been studied. OBJECTIVE: Our objective was to investigate the associations between elevated maternal LDL-C in pregnancy and CVD risk factors in 6-to-13-year-old offspring. METHODS: We recruited 6-to-13-year-old children whose mothers attended a pregnancy cohort and who had high or low cholesterol in pregnancy, defined as LDL-C over the 90th percentile or below the 10th percentile within the pregnancy cohort, respectively. We measured CVD risk factors in the children in the 2 groups. RESULTS: Maternal plasma LDL-C at gestational week 14 to 16 was 4.0 and 1.4 mmol/L in the hypercholesterolemic (n = 27) and hypocholesterolemic (n = 34) groups, respectively (P < .001). Interestingly, offspring plasma LDL-C was 0.4 mmol/L higher in children whose mothers had hypercholesterolemia during pregnancy (P < .01). We found no difference in birthweight or any other clinical or biochemical CVD risk factors or dietary intake between the children at 6-13 years. CONCLUSIONS: Women with elevated LDL-C during early pregnancy have offspring with higher LDL-C already at the age of 6-13 years. Unless cholesterol-reducing measures are successfully implemented, the affected children may be at increased cardiovascular risk. (C) 2016 National Lipid Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available